您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Sorafenib Tosylate(Bay 43-9006 Nexavar)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Sorafenib Tosylate(Bay 43-9006 Nexavar)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Sorafenib Tosylate(Bay 43-9006 Nexavar)图片
CAS NO:475207-59-1
规格:≥98%
包装与价格:
包装价格(元)
250mg电议
500mg电议
1g电议
2g电议
5g电议
10g电议
25g电议
50g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)637.03
FormulaC21H16ClF3N4O3.C7H8O3S
CAS No.475207-59-1(tosylate);
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 127 mg/mL (199.4 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: <1 mg/mL
SynonymBAY 43-9006 tosylate; BAY549085; BAY-439-006; BAY 549085; BAY-439006 tosylate; BAY 439006; BAY439006 tosylate; BAY-549085; Nexavar; SFN.
实验参考方法
GeneralOral administration of Sorafenib tosylate (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity.
Animal modelFemale NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
FormulationCremophor EL/ethanol (1:1) as 4-fold (4 × stock solution), and diluted to 1 × with w
Dosages60 mg/kg
AdministrationAdministered orally once a day
Reference[1] Wilhelm SM, et al. Cancer Res, 2004, 64(19), 7099-7109.
生物活性





The number of nuclei breaking the internal limiting membrane (ILM). A: Controlled group; B: ROP group; C: Vehicle-treated ROP group; D: Low doses sorafenib-treated ROP group; E: Middle doses sorafenib-treated ROP group; F: High dose sorafenib-treated ROP group.